Lindy Durrant appointed CEO of Scancell

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, is pleased to announce that Professor Lindy Durrant, founder, Board Director and Chief Scientific Officer of Scancell has been appointed Chief Executive Officer of Scancell Holdings plc with immediate effect. Professor Durrant was previously co-CEO of the Company. Dr Cliff Holloway has decided to step down as a Board Director and CEO, also with immediate effect. The Board would like to thank Cliff for his commitment over the last three years during which time the Company has made substantial progress.

Professor Lindy Durrant, said: "I believe Scancell has an unrivalled pipeline of products and I, along with the rest of the team at Scancell, intend to continue to drive our pipeline through the clinic as we focus on accelerating the development of what we believe to be our most commercially promising assets."

Dr Cliff Holloway, said: "Since I joined Scancell in early 2018 we've built and financed the Company to the point where it has a strong and diverse pipeline and it can now embark on its next phase of growth. I'm proud to have led Scancell during this pivotal time. The Company is now stronger than ever and I look forward to following its continued progress."

Dr John Chiplin, Executive Chairman, Scancell Holdings plc, commented: "As a founder and CSO, Lindy is the driving force behind Scancell's internationally recognised science. The Board firmly believes her strategic insight and commitment to moving products into the clinic as well as her strong leadership skills will deliver significant value to the business and to shareholders."

"We are very grateful to Cliff for all his hard work over the last three years at Scancell. The Company is now on a sound financial footing with the infrastructure in place for the next stage of its growth. The Board and I wish Cliff all the best for the future."